Connect with us

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website. .

Top Stories

FDA advisers back the same COVID vaccine for initial shots, boosters

2023 01 26T233300Z 2 LYNXMPEJ0P12P RTROPTP 4 HEALTH CORONAVIRUS - Global Banking | Finance

By Michael Erman and Leroy Leo

(Reuters) -Advisers to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of targeting the same coronavirus strain for initial COVID-19 vaccine doses and boosters going forward, but some expressed skepticism about whether all Americans need to receive the shots annually.

The agency is trying to simplify its COVID-19 vaccine policy as it considers whether to recommend Americans get an annual booster shot for the virus. But several members of the expert advisory group asked for more robust data on benefits of annual shots for younger, healthier people.

“We’re in a very different place. We have a lot of population immunity,” said Hayley Gans, professor of pediatrics at Stanford University Medical Center. “Now that people are immune, how long does that last?”

Vaccine makers Pfizer Inc with partner BioNTech SE and Moderna Inc introduced late last year updated versions of their COVID vaccines tailored to target Omicron variants as well as the original coronavirus. In the United States, those were used only as booster shots.

The FDA advisory group unanimously backed using those shots for the primary series for those who have yet to be vaccinated against COVID-19 as well.

The FDA said it envisioned holding a meeting later in the year to determine the composition of shots for the fall, although some vaccine makers might be able to produce updated shots more quickly.

Pfizer/BioNTech and Moderna were able to produce the currently available messenger RNA boosters in about three months last year, but Novavax Inc said on Thursday it would require six months to make a new version of its protein-based COVID-19 vaccine designed to match circulating coronavirus variants.

FDA would consider an earlier timeline for vaccines like Novavax’s following the company’s manufacturing assessment, Peter Marks, director of the agency’s Center for Biologics Evaluation & Research, said.

Health officials in the Biden administration have suggested that annual, updated COVID-19 booster shots could provide a high level of protection against severe disease.

(Reporting by Leroy Leo in Bengaluru, Michael Erman in Maplewood, New Jersey; Editing by Bill Berkrot)

 

Global Banking & Finance Review

 

Why waste money on news and opinions when you can access them for free?

Take advantage of our newsletter subscription and stay informed on the go!


By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review │ Banking │ Finance │ Technology. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Post